
AACR 2019: Two KEYNOTE trials show pembrolizumab benefit for advanced SCLC
The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumour activity with durable responses in patients…
The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumour activity with durable responses in patients…